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PDGF-BB: Platelet-derived growth factor-BB 
RACs:  Regeneration-associated cells  
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TNF-: Tumour necrosis factor- 
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Ischaemic stroke is a debilitating disease with immense personal, societal and economic impact. 
Thrombolysis with recombinant tissue plasminogen activator remains the only approved 
pharmacotherapy for this disease. As each year less than 1% of eligible patients receive this therapy 
worldwide, efficacious new therapeutics are desperately needed. Emerging evidence suggest 
endothelial progenitor cells (EPCs), capable of repairing damaged vasculature, as one such 
therapeutics. However, questions regarding their optimal dose, delivery route and in vivo 
survivability remain largely unanswered. Outgrowth endothelial cells, generated in large numbers 
by ex vivo expansion of EPCs, enable effective assessment of these issues and may eventually serve 
as off-the-shelf therapeutics. Correlations between circulating EPC levels and stroke outcome 
imply that EPCs may also serve as clinical biomarkers for stroke. This viewpoint briefly evaluates 

















Stroke annually affects about 13.5 million people worldwide and constitutes one of the leading 
causes of mortality and morbidity (Virani et al., 2021). Ischaemic stroke, stemming from the 
occlusion of an artery leading to the brain, represents the major subtype of stroke and accounts for 
approximately 85% of all strokes in the Western world (Hisham and Bayraktutan, 2013). At 
present, reperfusion therapy with recombinant tissue plasminogen activator (rtPA) and mechanical 
thrombectomy are the only approved treatment options for acute IS. However, due to short 
therapeutic windows associated with these treatment regimens, each year globally <1% of patients 
receive these therapies (Malhotra et al., 2019; Virani et al., 2021). 
 
The pathophysiology of stroke is complex and involves many interrelated processes, including 
depletion of ATP, apoptosis, necrosis, excitotoxicity, inflammation, oxidative stress and an abrupt 
surge in intracellular calcium levels (Allen and Bayraktutan, 2008; Rakkar and Bayraktutan, 2016). 
Despite having tremendous success in preclinical studies, agents targeting these particular 
mechanisms have failed to produce similar benefits in clinical trials. The incessant failure of 
clinical trials with the so-called neuroprotectants prompted search for alternative therapeutics and 
placed cell-based therapeutic approaches targeting cerebrovascular integrity at the forefront of 
clinical investigation. Given that disruption of blood-brain barrier (BBB) and ensuing cerebral 
oedema constitute the main cause of death within the first week after an IS, adoption of a vascular 
restorative/reparative approach was somewhat inevitable (Hou and McManus, 2002; Dankbaar et 
al., 2011). In this context, endothelial progenitor cells (EPCs), capable of angiogenesis, 
vasculogenesis, self-renewal and differentiation into mature endothelial cells, have attracted much 





Overview of EPCs as therapeutics  
Phase I studies, performed with bone marrow-derived mononuclear stem cells (BMSCs) or CD34+ 
cells known to contain a population of progenitor cells, prove the safety and feasibility of 
intravenous and intra-arterial infusion of EPCs during the (sub)acute phase of IS (Fang et al., 2019; 
Savitz et al., 2011). Despite confirming these findings, a randomised, multicentre study using 
BMSCs yielded no benefit on stroke outcome (Prasad et al., 2014). Preclinical studies, investigating 
the degree of EPC incorporation into the damaged vasculature as a measure of therapeutic efficacy, 
also report inconsistent results in terms of functional outcome (Purhonen et al, 2008; Garbuzova-
Davis et al., 2017; Hong et al., 2020). Indeed, while robust engraftment of intravenously 
administered human bone marrow EPCs within capillaries is associated with widespread repair of 
vasculature and near normal morphology of endothelial cells, astrocytes and pericytes in bilateral 
striatum and motor cortex of a rodent model of transient IS (Garbuzova-Davis et al., 2017), studies 
showing inability of circulating EPCs to engraft vasculature also exists (Hagensen et al., 2012). As 
ambiguities regarding the nature of EPCs somewhat account for these discrepancies, it is of utmost 
importance to standardise the definition of EPCs in order to accurately evaluate their therapeutic 
efficacy. As alluded above, CD34+ cells, isolated from peripheral blood by fluorescence activated 
cell sorting, are described in various studies as EPCs (Banarjee et al., 2014; Shyu et al., 2006). 
Although shown to promote revascularisation in ischaemic hearts and brains, it is unlikely that 
these haematopoietic stem cells can actually be true EPCs (Chen et al., 2014; Sobrino et al., 2011). 
Because, EPCs possess embryonic angioblast-like characteristics and are the precursors of mature 
endothelial cells, it is likely that only few circulating nonhaematopoietic cells (e.g. CD45- or CD14-
), concomitantly expressing markers for stemness (e.g. CD34+ or CD117+), immaturity (e.g. 
CD133+) and endothelial cells (e.g. KDR+ or CD31+), may make up the true EPCs. It is of note 
that a recent study suggests ephrinB2 and bone morphogenetic protein 2 and 4 as important novel 
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markers for identification and characterisation of EPC subpopulation in adult peripheral blood 
(Abdelgawad et al., 2021). 
 
In addition to repairing vascular damage, EPCs can also stimulate the process of endogenous 
recovery by immunomodulation and secretion of various trophic factors, notably stromal-derived 
factor-1, angiopoietin-1, vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
and platelet-derived growth factor-BB (Ohab et al., 2006; Rosell et al., 2013).  Enhanced functional 
recovery coupled with decreases in infarct volume, angiogenesis and anti-inflammatory cytokine 
release provide indirect evidence for the beneficial effects of stem cells (and their secretome) in 
animal models of stroke (Di Santo et al., 2009; Rosell et al., 2013). Our recent studies probing how 
EPCs, defined as CD45-CD34+CD133+KDR+ cells, may affect the integrity and function of an in 
vitro model of human BBB subjected to ischaemic injury or TNF-, a key cytokine during the post-
stroke inflammation, offers convincing direct evidence for their protective effects in that 
suppression of stress fibre formation, oxidative stress and apoptosis play a pivotal role (Abdulkadir 
et al., 2020; Alwjwaj et al, 2021). Crucially, these studies also indicate that much of the EPC-
mediated beneficial effects are realised by their secretome and thus necessitate the scrutiny of EPC 
secretome as a potential therapeutic for IS. Microparticles, containing DNA, RNA and microRNAs, 
represent an important constituent of the secretome and deserve attention in future studies due to 
their seminal role in inducing vascular endothelial regeneration via promotion of tissue-resident 
endothelial cell proliferation and migration (Kadir et al., 2020). Concurrent manipulation of other 
key factors known to mediate mobilisation, homing and differentiation of EPCs, such as VEGF, 
stromal derived factor-1 and interleukin-10 also deserve attention in relevant future studies 





EPCs as clinical biomarkers 
Since EPCs repair the damaged vasculature and can also work as proangiogenic support cells, the 
number of circulating EPCs is widely considered as a reliable diagnostic and/or prognostic marker 
for IS. Indeed, observational studies scrutinising the correlation between EPC number and stroke 
outcome have correlated the increased cell numbers in acute and subacute phases of the disease to 
greater vascular repair, endothelial restoration and better clinical outcome (Paczkowska et al., 
2009; Marti-Fabregas et al., 2013). However, investigations reporting lower baseline levels of 
circulating EPCs in acute IS patients compared to healthy volunteers also exist (Tsai et al., 2014). 
In addition to EPC number, variations in the capacity of cultured EPCs to migrate, proliferate and 
form tubules and colonies are also regarded as important diagnostic and prognostic markers for IS. 
Even so, the current data on these EPC characteristics during different phases of stroke, particularly 
chronic phase, are rather scant and controversial. Besides, exclusion of healthy volunteers from 
most studies make it difficult to interpret the data generated (Chu et al., 2008; Marti-Fabregas et 
al., 2013; Zhou et al., 2009). Considering the gap in the literature and bearing in mind the close 
association reported between EPC numbers and different subtypes of stroke (Tsai et al., 2014), a 
recent study has longitudinally assessed the diagnostic and prognostic value of EPCs in elderly 
patients with lacunar or cortical stroke during acute, subacute and chronic phases of the disease 
(Rakkar et al., 2020). By recruiting both elderly (≥65 years) and young (18-64 years) healthy 
volunteers, this study has also addressed the specific association between EPC characteristics 
(number and functional aspects) and chronological ageing, a prominent risk factor for IS. The data 
indicate that ageing process and other vascular risk factors, including hypertension and diabetes, 
adversely affect the release and function of EPCs in healthy volunteers and the count and function 





OEC therapy for stroke 
Cell culture, based on adhesion of cells to specific substrates, e.g. collagen, before culture in 
endothelial cell specific media is recognised as the best methodology to generate adequate numbers 
of homogeneous cells for therapeutic purposes. This procedure leads to generation of two 
functionally and morphologically distinct EPC subtypes: early EPCs (eEPCs) and outgrowth 
endothelial cells (OECs), also known as endothelial colony forming cells (Bayraktutan, 2019). The 
molecular profiling of early EPCs classifies them as haematopoietic cells (Medina et al., 2010a). 
OECs, on the other hand, constitute the functional subtype of EPCs and display strong proliferative, 
migratory and tubulogenic capacity in vitro. OECs also express endothelial and progenitor cell 
markers which differentiate them from haematopoietic cells and circulating mature endothelial 
cells, respectively (Abdulkadir et al., 2020). Attempts to expand OECs ex vivo have shown that 
after a certain number of passages, OECs go into senescence and display classical markers of 
senescence including enlarged cellular phenotype, S--galactosidase activity and DNA damage. 
Albeit associated with dysfunctionality and limited regenerative potential, OEC senescence is also 
associated with the reduced risk of tumourigenesis, indicating their safety in vivo (Medina et al., 
2013). Ability of OECs to lodge and survive in nine different vascular beds for up to 7 months after 
injection without inducing any thrombosis or infarcts confirm their long-term efficacy and safety 
(Milbauer et al., 2009). Through modulation of key mechanisms involved in OEC senescence, such 
as interleukin-8 and growth differentiation function 15, it is possible to delay senescence in a 
controlled manner and/or improve vascular functionality (Medina et al., 2013; Ha et al., 2019).  
 
Key features that make OECs potentially a very effective cell-based therapeutic include that OECs 
repair post-ischaemic vascular injuries by directly incorporating into host endothelium and 
inducing angiogenesis. Significant decreases in avascular areas in a murine model of retinal 
ischemia and improvements in cardiac function in a porcine model of acute myocardial infarction 
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support this hypothesis (Medina et al., 2010b; Dubois et al., 2010). Other features include that 
OECs can be expanded from patients’ own blood for autologous therapy which markedly eliminate 
the risk of rejection. However, the time needed to cultivate the number of cells required for 
transplantation restricts autologous therapy to chronic phases of disease and necessitates 
consideration of an allogeneic approach for patients with acute and subacute stroke. Albeit 
conceptually fraught with immunological risk, a meta-analysis of large animals with ischaemic 
heart disease has shown that both autologous and allogeneic cell therapies are equally safe and 
efficacious (Jansen et al., 2015). Detection of a greater tissue repair in acute ischaemic stroke 
patients at one year of receiving intravenously injected allogeneic cells further confirm the safety 
of this therapeutic approach (Vaes et al., 2012) where suppression of both CD4 and CD8 T cells 
proliferation and activation by EPCs may be crucial (Naserian et al., 2020). It may be possible to 
further augment the immunosuppressive capacity of EPCs by priming them with TNF- to 
specifically activate TNF/TNFR2 (TNF- receptor 2) signalling pathway before administration 
(Barkestani et al., 2021). Creation of cell banks with detailed characterisation of HLA haplotypes 
matching population requirements and use of immunologically immature cord blood-OECs may 
also help address immune-(in)compatibility issue. By mediating the secretion of both interleukin-
10, an anti-inflammatory cytokine and transforming growth factor-1, (TGF-1), cord blood-OECs 
restore a functional vascular network under ischaemic conditions in immunocompetent mice 
(Proust et al., 2020). TGF-1 is a multifunctional protein that plays a crucial role in the formation 
of blood vessels, wound healing and inflammatory processes in the immune system (Fujio et al., 
2016;).  
 
Administration of regeneration-associated cells (RACs) may be an alternative approach to 
potentiate the therapeutic efficacy of EPCs in ischaemic diseases. RACs, obtained by vasculogenic 
conditioning of peripheral mononuclear cells in the presence of human recombinant stem cell 
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factor, thrombopoietin, Flt-3 ligand, VEGF and interleukin-6, can enhance EPC expansion and 
activate anti-inflammatory and angiogenic monocytes/macrophages and helper T lymphocytes 
(Masuda et al., 2012; Masuda et al., 2014). In accordance with these findings, administration of 
RACs to an animal model of human transient IS during the acute phase of ischaemic injury has 
successfully reduced infarct volume and promoted significant recovery of neural tissues through 
intensified angiogenic and anti-inflammatory effects (Nakayama et al., 2019). 
 
Future Issues for Consideration 
As summarised in figure 1, due to extremely low level of true EPCs in circulation, it is highly 
unlikely to sort sufficient number of cells from peripheral blood that can be used for therapeutic 
purposes. OECs, the functional subtype of EPCs generated by cell culture, appear to be a highly 
promising therapeutics with immense potential for post-ischaemic vascular repair, vasculogenesis, 
angiogenesis and possibly neurogenesis (Takizawa et al., 2016, Bayraktutan, 2019). Although 
limited replicative potential and the current immunological understanding, based on animal and 
clinical data, support the use of allogeneic therapy, various issues concerning the survivability, in 
vivo tracking, optimal dose and delivery route need clarification. Furthermore, questions regarding 
tolerance to repeat OEC dosing need to be addressed. Should cells from a different donor be used 
to avoid anamnestic reaction? Also, questions regarding the co-application of OECs with other 
stem cells or agents targeting oxidative stress, inflammation or increased intracellular Ca2+ levels 
need to be addressed. How would these applications affect the therapeutic impact of OECs? 
Similarly, questions regarding immunological reactions also need to be addressed. Should HLA-
matching be performed before administration of OECs? Should immunological reaction alongside 




In conclusion, well-planned comprehensive studies, monitoring the levels and functional capacity 
of circulating EPCs and the immunologic profile of the recipients, are needed to unravel the true 




Figure 1: Summary of the main processes by which endothelial progenitor cells (EPCs) are 
obtained from peripheral blood and used for clinical purposes. EPCs can serve as diagnostic, 
prognostic or therapeutic biomarkers for ischaemic stroke. Alternatively, EPCs may be sorted by 
FACS or expanded by cell culture to obtain a large number of homogenous cells which successively 
yield CD34+ cells and outgrowth endothelial cells (OECs). These then can be used as efficacious 
therapeutics in autologous or allogeneic therapies. 
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